Lenalidomid Medical Valley (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma cells and dysplastic clones.

• Multiple Myeloma (newly diagnosed): improves progression‑free and overall survival.
• Multiple Myeloma (relapsed/refractory): provides disease control when other therapies have failed.
• Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and improves blood counts.

• Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity. This leads to degradation of transcription factors Ikaros and Aiolos, resulting in modulation of cytokine production, inhibition of angiogenesis, and induction of apoptosis in malignant plasma cells and dysplastic hematopoietic clones.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fatigue: persistent tiredness reported by many patients.
• Neutropenia: reduced neutrophil count increasing infection risk.
• Thrombocytopenia: low platelet levels leading to easy bruising.
• Diarrhea: loose stools that may require management.
• Rash: skin eruptions of varying intensity.
• Constipation: difficulty passing stools.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Secondary primary malignancies: emergence of new cancers.
• Severe neutropenia: profound immune suppression.
• Hepatic toxicity: elevated liver enzymes or liver injury.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Lenalidomid Medical Valley requires careful monitoring and specific safety measures.

• Pregnancy: contraindicated (Category X); avoid use in pregnant women.
• Thrombosis risk: assess patient history and consider prophylactic anticoagulation.
• Renal impairment: adjust dosing and monitor kidney function.
• Hematologic monitoring: perform regular complete blood counts.
• Drug interactions: review concomitant medications for potential interactions.
• Store below 25°C: keep in the original pack, protect from moisture.

Lenalidomid Medical Valley can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly lower lenalidomide exposure.
• Anticoagulants (warfarin): increased risk of bleeding.
• Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (aspirin, clopidogrel): monitor for bleeding signs.
• HIV protease inhibitors (ritonavir): may raise lenalidomide plasma levels.
• Diuretics (furosemide): watch electrolyte balance and renal function.